financetom
Business
financetom
/
Business
/
Mastek poised for exponential growth in FY24, surpassing industry's high-single digit expansion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mastek poised for exponential growth in FY24, surpassing industry's high-single digit expansion
Jun 9, 2023 3:16 AM

Hiral Chandrana, the Global CEO of Mastek, in an interview with CNBC-TV18, expressed his optimism regarding the company's growth prospects, despite the challenges faced by the industry. Chandrana firmly believes that Mastek is well-positioned to surpass the industry average and achieve remarkable growth in the fiscal year 2024.

Share Market Live

NSE

While he anticipates the industry to experience growth in the high-single digits during this period, he confidently asserts that Mastek's growth rate will outpace the industry.

Chandrana stated, "While some players in the industry are projecting a more subdued forecast for the year, we have laid a strong foundation for an overall industry-leading growth in FY24. Our pipeline and the momentum of deals going into the year have been exceptionally positive, fueling our optimism for the remainder of the year."

Although Chandrana maintains a cautious optimism at the beginning of FY24, considering the decision-making delays prevalent in the industry, he emphasized that Mastek possesses a solid foundation for achieving substantial growth during this fiscal year. With a margin aspiration in the high teens, the company aims to not only drive expansion but also achieve profitability along the way.

Read Here | Infosys shares can deliver up to 18% return despite near-term weakness — should you buy?

“The high teens is still what we want to maintain from an outlook perspective, we don't guide as you know, but we feel comfortable in the range that we are in. We feel this is the right kind of level. Over a period of time, we do want to get closer to that 19-20 percent range, but this 18 percent range is a is a comfortable range for us,” Chandrana added.

The UK market, in particular, has witnessed deals ranging from $10-25 million in the past, indicating substantial opportunities for Mastek.

Mastek's presence in the US and the Middle East has also yielded positive results, with deals falling in the range of $5-10 million. To further bolster its growth strategy, the company is placing significant emphasis on client account mining.

Also Read | RBI MPC Meet 2023: Unanimous decision to leave repo rate unchanged at 6.5%

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell
Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell
Apr 2, 2025
08:51 AM EDT, 04/02/2025 (MT Newswires) -- Sunshine Biopharma ( SBFM ) said Wednesday that it completed additional studies of its K1.1 mRNA lipid nanoparticle product, which confirmed it as a novel therapeutic agent for liver cancer. Under repeated dosing, the mRNA product was found to reduce the growth of three different types of human hepatocellular carcinoma tumors in mice,...
Sector Update: Consumer
Sector Update: Consumer
Apr 2, 2025
08:50 AM EDT, 04/02/2025 (MT Newswires) -- Consumer stocks were mixed premarket Wednesday, with The Consumer Staples Select Sector SPDR Fund (XLP) marginally higher and The Consumer Discretionary Select Sector SPDR Fund (XLY) down 1.3%. Innovation Beverage Group ( IBG ) shares were up past 196% after the company said it has signed a distribution agreement with Republic National Distribution....
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share
Apr 2, 2025
08:55 AM EDT, 04/02/2025 (MT Newswires) -- Allakos ( ALLK ) shares were over 45% higher in recent premarket trading Wednesday after the company said it has entered into a definitive agreement to be acquired by Concentra Biosciences. Under the merger agreement, a Concentra subsidiary will start a tender offer to acquire all outstanding shares of Allakos ( ALLK )...
IBM Extends Semiconductor Partnership With Tokyo Electron by Five Years
IBM Extends Semiconductor Partnership With Tokyo Electron by Five Years
Apr 2, 2025
08:52 AM EDT, 04/02/2025 (MT Newswires) -- International Business Machines ( IBM ) said Wednesday that it has extended its partnership with Tokyo Electron to research and develop advanced semiconductor technologies for another five years. The company said the new agreement will focus on progressing technology for semiconductor nodes and architectures designed for generative artificial intelligence. Shares of IBM (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved